Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial)".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the USFDA for its generic Pantoprazole Sodium for Injection in the 40 mg single-dose vial format. Pantoprazole is a proton pump inhibitor commonly used in hospitals to treat acid reflux, GERD, and related stomach conditions. With final approval in hand, Alembic is now cleared to commercially launch this product in the US market. This adds another injectable product to Alembic's US generics portfolio. The approval strengthens the company's presence in the US institutional/hospital channel, where injectables tend to command steady demand.
Positive for the company — USFDA final approval opens the door to US market sales of this generic injectable, which can contribute to revenue growth. For shareholders, this is a routine but welcome addition to Alembic's US pipeline, though the typical price erosion in generics means the long-term value depends on volume share captured.